N/A
Completed N=126
NeoChord TACT Post-Market Surveillance Registry
Source: ClinicalTrials.gov NCT01784055 ↗Enrolled (actual)
126
Serious AEs
29.4%
Results posted
Apr 2018
Primary outcomePrimary: Procedure Success — 121; 5 Participants
Summary
To monitor the long-term performance of the CE Marked NeoChord Artificial Chordae Delivery System
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Procedure Success |
121; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Grade 3+ or 4+ mitral valve regurgitation
Exclusion Criteria
- Heavily calcified valves
- Valvular retraction with severely reduced mobility
- Active bacterial endocarditis
- Complex mechanism of MR (leaflet perforation, etc.)
- Significant tethering of leaflets
- Inflammatory valve disease
Data sourced from ClinicalTrials.gov (NCT01784055). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.